Limitations of galactose therapy in phosphoglucomutase 1 deficiency

about

CDG Therapies: From Bench to Bedside.

P2860

Q52558429-45DE7A10-A64D-4D0A-8E6C-CA486351351A

P2860

Limitations of galactose therapy in phosphoglucomutase 1 deficiency

Item

http://www.wikidata.org/entity/Q41220043

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Limitations of galactose therapy in phosphoglucomutase 1 deficiency

@en

type

Item

label

Limitations of galactose therapy in phosphoglucomutase 1 deficiency

@en

prefLabel

Limitations of galactose therapy in phosphoglucomutase 1 deficiency

@en

P1476

Limitations of galactose therapy in phosphoglucomutase 1 deficiency

@en

P2093

Andrea Zühlsdorf

http://www.w3.org/2001/XMLSchema#string

Christian Thiel

http://www.w3.org/2001/XMLSchema#string

Eric Schulze-Bahr

http://www.w3.org/2001/XMLSchema#string

Ingrid Du Chesne

http://www.w3.org/2001/XMLSchema#string

Janine Reunert

http://www.w3.org/2001/XMLSchema#string

Kristine Nolting

http://www.w3.org/2001/XMLSchema#string

Laura C Tegtmeyer

http://www.w3.org/2001/XMLSchema#string

Marianne Grüneberg

http://www.w3.org/2001/XMLSchema#string

Ralph Fingerhut

http://www.w3.org/2001/XMLSchema#string

Robert C Baxter

http://www.w3.org/2001/XMLSchema#string

P2860

Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy

Galactose toxicity in animals

Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG

Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes

Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3

Chronic Uridine Administration Induces Fatty Liver and Pre-Diabetic Conditions in Mice

Impaired binding of ZASP/Cypher with phosphoglucomutase 1 is associated with dilated cardiomyopathy

Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics.

Multiple phenotypes in phosphoglucomutase 1 deficiency.

Cardiomyopathy in congenital disorders of glycosylation.

P304

33-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YMGMR.2017.07.010

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emile Van Schaftingen

Julien H Park

P577

2017-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28794993

http://www.w3.org/2001/XMLSchema#string

P932

5540825

http://www.w3.org/2001/XMLSchema#string

Limitations of galactose therapy in phosphoglucomutase 1 deficiency

about

P2860

P2860

Limitations of galactose therapy in phosphoglucomutase 1 deficiency

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932